MacroGenics, Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 3,066,926 shares of MacroGenics common stock, representing 4.8% of the class. The reporting persons state they acquired beneficial ownership of more than 5% on 05/08/2026 and ceased to be beneficial owners of more than 5% by the date of this filing. The filing is submitted jointly and includes a Joint Filing Agreement dated 05/13/2026.
Positive
None.
Negative
None.
Insights
Large asset manager reported a sub-5% stake after briefly exceeding 5%.
The filing shows 3,066,926 shares held with shared voting and dispositive power, reported as 4.8% of the outstanding common stock. The report also states a prior threshold event on 05/08/2026.
Investor impact depends on future disclosures about changes in the position; subsequent filings would show whether this represents active repositioning or portfolio reshuffling.
Joint filing and control language emphasize aggregated reporting, not direct ownership admission.
The schedule clarifies that securities are held by entities subject to voting control or investment discretion by the reporting entities and that those statements "should not be construed" as admissions of beneficial ownership.
Signatories include Gil Raviv and Israel A. Englander and attach a Joint Filing Agreement dated 05/13/2026.
Key Figures
Reported shares:3,066,926 sharesPercent of class:4.8%Threshold event date:05/08/2026+1 more
4 metrics
Reported shares3,066,926 sharesshared beneficial ownership reported on the cover pages
Percent of class4.8%percent of MacroGenics common stock as stated on cover pages
Threshold event date05/08/2026date reporting persons acquired beneficial ownership of more than 5%
Joint Filing Agreement date05/13/2026date of attached Joint Filing Agreement among reporting persons
"Schedule 13G appears as the form type on the cover"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficial ownershipfinancial
"Language notes "beneficially owned" and references to Item 9 on the cover pages"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Joint Filing Agreementlegal
"Exhibit I: Joint Filing Agreement, dated as of May 13, 2026"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
MacroGenics, Inc.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
556099109
(CUSIP Number)
05/08/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
556099109
1
Names of Reporting Persons
Millennium Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,066,926.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,066,926.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,066,926.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
556099109
1
Names of Reporting Persons
Millennium Group Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,066,926.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,066,926.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,066,926.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
556099109
1
Names of Reporting Persons
Israel A. Englander
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,066,926.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,066,926.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,066,926.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
MacroGenics, Inc.
(b)
Address of issuer's principal executive offices:
9704 Medical Center Drive, Rockville, Maryland 20850
Item 2.
(a)
Name of person filing:
Millennium Management LLC
Millennium Group Management LLC
Israel A. Englander
(b)
Address or principal business office or, if none, residence:
Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Group Management LLC
399 Park Avenue
New York, New York 10022
Israel A. Englander
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
(c)
Citizenship:
Millennium Management LLC - Delaware
Millennium Group Management LLC - Delaware
Israel A. Englander - United States
(d)
Title of class of securities:
Common Stock, par value $0.01 per share
(e)
CUSIP Number(s):
556099109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See response to Item 9 on each cover page.
After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on May 8, 2026, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.
(b)
Percent of class:
See response to Item 11 on each cover page.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See response to Item 5 on each cover page.
(ii) Shared power to vote or to direct the vote:
See response to Item 6 on each cover page.
(iii) Sole power to dispose or to direct the disposition of:
See response to Item 7 on each cover page.
(iv) Shared power to dispose or to direct the disposition of:
See response to Item 8 on each cover page.
The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit I
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Millennium Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
05/13/2026
Millennium Group Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
05/13/2026
Israel A. Englander
Signature:
/s/ Israel A. Englander
Name/Title:
Israel A. Englander
Date:
05/13/2026
Exhibit Information
Exhibit I: Joint Filing Agreement, dated as of May 13, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
What stake did Millennium report in MacroGenics (MGNX)?
The filing lists 3,066,926 shares, representing 4.8% of MacroGenics common stock. The figure is reported with shared voting and dispositive power by the reporting persons.
Did Millennium ever exceed the 5% ownership threshold in MGNX?
Yes. The filing states the reporting persons acquired beneficial ownership of more than 5% on 05/08/2026. They report they ceased to be >5% by the filing date.
Who signed the Schedule 13G for MacroGenics?
The schedule is signed by Gil Raviv as Global General Counsel and by Israel A. Englander, with a Joint Filing Agreement dated 05/13/2026 attached.
How is the reported ownership held or controlled?
The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and other managers; the filing disclaims that this alone is an admission of beneficial ownership.
What class of securities is covered in this filing?
The filing covers Common Stock, par value $0.01 per share of MacroGenics, with CUSIP number 556099109 listed on the cover.
